Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
By
Lauran Neergaard
A good honest bake. Not flashy, but you'll finish the whole bagel.
Summary
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug blocks a mutated protein (KRAS) that fuels tumor growth in over 90% of pancreatic cancer cases — a target that had eluded treatment for decades. In clinical trials, the daily pills nearly doubled survival time. While not a cure, researchers describe it as a significant step forward for one of the deadliest cancers.
Key quotes
· 2 pulledWhile not curing the cancer, it is a very large step forward.
The drug blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades.
You might also wanna read
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·20h ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·3mo ago